Literature DB >> 12066445

Neuroactive steroids and anxiety disorders.

Jean-Michel Le Mellédo1, Glen B Baker.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12066445      PMCID： PMC161645     

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN： 1180-4882            Impact factor:   6.186


× No keyword cloud information.
  30 in total

Review 1.  Protective and damaging effects of mediators of stress. Elaborating and testing the concepts of allostasis and allostatic load.

Authors:  B S McEwen; T Seeman
Journal:  Ann N Y Acad Sci       Date:  1999       Impact factor: 5.691

2.  Neuroactive steroid changes in response to challenge with the panicogenic agent pentagastrin.

Authors:  Glendon R Tait; Karen McManus; François Bellavance; Nathalie Lara; Wendy Chrapko; Jean-Michel Le Mellédo
Journal:  Psychoneuroendocrinology       Date:  2002-05       Impact factor: 4.905

3.  Behavioral, biochemical, and blood pressure responses to alprazolam in healthy subjects: interactions with yohimbine.

Authors:  D S Charney; A Breier; P I Jatlow; G R Heninger
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

Review 4.  Neurosteroids: beginning of the story.

Authors:  E E Baulieu; P Robel; M Schumacher
Journal:  Int Rev Neurobiol       Date:  2001       Impact factor: 3.230

5.  Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes.

Authors:  L D Griffin; S H Mellon
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-09       Impact factor: 11.205

6.  GABA(A) receptor-modulating neuroactive steroid composition in patients with panic disorder before and during paroxetine treatment.

Authors:  Andreas Ströhle; Elena Romeo; Flavia di Michele; Augusto Pasini; Alexander Yassouridis; Florian Holsboer; Rainer Rupprecht
Journal:  Am J Psychiatry       Date:  2002-01       Impact factor: 18.112

7.  Elevated circulatory level of GABA(A)--antagonistic neurosteroids in patients with combat-related post-traumatic stress disorder.

Authors:  B Spivak; R Maayan; M Kotler; R Mester; I Gil-Ad; B Shtaif; A Weizman
Journal:  Psychol Med       Date:  2000-09       Impact factor: 7.723

8.  Pregnenolone sulfate: a positive allosteric modulator at the N-methyl-D-aspartate receptor.

Authors:  F S Wu; T T Gibbs; D H Farb
Journal:  Mol Pharmacol       Date:  1991-09       Impact factor: 4.436

9.  Stress-induced elevations of gamma-aminobutyric acid type A receptor-active steroids in the rat brain.

Authors:  R H Purdy; A L Morrow; P H Moore; S M Paul
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-15       Impact factor: 11.205

10.  Neurotransmitter modulation of corticotropin releasing factor secretion into the hypophysial-portal circulation.

Authors:  P M Plotsky; S Otto; S Sutton
Journal:  Life Sci       Date:  1987-09-07       Impact factor: 5.037
View more
  13 in total

Review 1.  Fluoxetine and norfluoxetine stereospecifically and selectively increase brain neurosteroid content at doses that are inactive on 5-HT reuptake.

Authors:  Graziano Pinna; Erminio Costa; Alessandro Guidotti
Journal:  Psychopharmacology (Berl)       Date:  2006-01-24       Impact factor: 4.530

2.  Development of a radioligand for imaging V1a vasopressin receptors with PET.

Authors:  Ravi Naik; Heather Valentine; Andrew Hall; William B Mathews; James C Harris; C Sue Carter; Robert F Dannals; Dean F Wong; Andrew G Horti
Journal:  Eur J Med Chem       Date:  2017-08-18       Impact factor: 6.514

3.  Impaired neurosteroid synthesis in multiple sclerosis.

Authors:  Farshid Noorbakhsh; Kristofor K Ellestad; Ferdinand Maingat; Kenneth G Warren; May H Han; Lawrence Steinman; Glen B Baker; Christopher Power
Journal:  Brain       Date:  2011-09       Impact factor: 13.501

Review 4.  The relevance of neuroactive steroids in schizophrenia, depression, and anxiety disorders.

Authors:  Erin M MacKenzie; John Odontiadis; Jean-Michel Le Mellédo; Trevor I Prior; Glen B I Baker
Journal:  Cell Mol Neurobiol       Date:  2007-08       Impact factor: 5.046

5.  Preliminary evidence for an association between aggressive and hostile behaviour and 3alpha,5alpha-tetrahydroprogesterone plasma levels in schizophrenia.

Authors:  Gianfranco Spalletta; Elena Romeo; Giuseppina Bonaviri; Giorgio Bernardi; Carlo Caltagirone; Flavia di Michele
Journal:  J Psychiatry Neurosci       Date:  2005-01       Impact factor: 6.186

Review 6.  Neurosteroids' effects and mechanisms for social, cognitive, emotional, and physical functions.

Authors:  Cheryl A Frye
Journal:  Psychoneuroendocrinology       Date:  2009-12       Impact factor: 4.905

7.  Dysregulation of neurosteroids in obsessive compulsive disorder.

Authors:  K L Bigos; M M Folan; M R Jones; G L Haas; F J Kroboth; P D Kroboth
Journal:  J Psychiatr Res       Date:  2008-06-02       Impact factor: 4.791

Review 8.  Circadian rhythms in obsessive-compulsive disorder.

Authors:  Klaus W Lange; Katharina M Lange; Joachim Hauser; Lara Tucha; Oliver Tucha
Journal:  J Neural Transm (Vienna)       Date:  2012-04-28       Impact factor: 3.575

9.  Effects and Mechanisms of 3α,5α,-THP on Emotion, Motivation, and Reward Functions Involving Pregnane Xenobiotic Receptor.

Authors:  Cheryl A Frye; J J Paris; A A Walf; J C Rusconi
Journal:  Front Neurosci       Date:  2012-01-19       Impact factor: 4.677

Review 10.  Neuroactive Steroids: Receptor Interactions and Responses.

Authors:  Kald Beshir Tuem; Tesfay Mehari Atey
Journal:  Front Neurol       Date:  2017-08-28       Impact factor: 4.003
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.